Massive Asymptomatic Creatine Kinase Elevation in Youth During Antipsychotic Drug Treatment: Case Reports and Critical Review of the Literature
Autor: | Valentina Viglione, Gabriele Masi, Alice Mancini, Annarita Milone, Simone Pisano |
---|---|
Rok vydání: | 2014 |
Předmět: |
Male
Tachycardia medicine.medical_specialty Weakness Adolescent medicine.medical_treatment Asymptomatic Rhabdomyolysis Internal medicine Humans Neuroleptic Malignant Syndrome Medicine Pharmacology (medical) Antipsychotic drug Antipsychotic Creatine Kinase biology business.industry medicine.disease Neuroleptic malignant syndrome Psychiatry and Mental health Pediatrics Perinatology and Child Health biology.protein Physical therapy Creatine kinase Drug Monitoring medicine.symptom business Antipsychotic Agents |
Zdroj: | Journal of Child and Adolescent Psychopharmacology. 24:536-542 |
ISSN: | 1557-8992 1044-5463 |
DOI: | 10.1089/cap.2014.0047 |
Popis: | A massive asymptomatic creatine kinase elevation (MACKE) has been described during antipsychotic exposure in adult psychotic patients without signs of neuroleptic malignant syndrome (NMS), or other most frequent reasons for high creatine kinase (CK) serum level (intramuscular injections, restraints, intense physical activity, dystonic reactions). In this article, we review this clinical condition, and report three cases of MACKE in nonpsychotic, drug-naïve youth during treatment with second generation antipsychotics. The diagnosis of MACKE should be considered after ruling out other possible common reasons of CK increase. The finding of MACKE should indicate a need for weekly monitoring of the CK level only when there are reasons to believe elevated CK is toxic or harmful. Further investigations are recommended when signs and symptoms raise a suspicion of NMS or rhabdomyolysis, including flu-like syndrome, fever, weakness, alteration of consciousness, muscle rigidity, tachycardia, hyper-/hypotension, and dark urine. A drug discontinuation should be considered when possible signs of NMS or rhabdomyolysis are suspected, or in cases of very high and persisting CK levels. Empirical evidence indicates that there is not a "safe" antipsychotic medication; therefore, a switch to another antipsychotic with a different profile is not necessarily a safe option. The spontaneously remitting or intermittent course suggests that the "true" MACKE should be kept distinct from both rhabdomyolysis and NMS. Raising awareness with MACKE may reduce the need for unnecessary diagnosis of NMS or rhabdomyolysis, which may otherwise lead to an unnecessary discontinuation of an effective therapeutic agent. |
Databáze: | OpenAIRE |
Externí odkaz: |